Genmab CEO: A year focused on daratumumab
Genmab CEO Jan van de Winkel admits that the market has been turbulent as of late, but the Danish company has come out the other side and keeps its eye on the prize: drug candidate daratumumab.
by Benjamin Werner Christensen
Jan van de Winkel and his colleagues at Genmab will be focusing great attention on the further development of the company’s great drug hope, daratumumab, for the treatment of the bone marrow cancer disease, multiple myeloma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab’s drug hope is failing
For abonnenter
Genmab CEO: Important data on the horizon
For abonnenter
The boss’s plan: New Genmab a force to be reckoned with
For abonnenter
